LVW Advisors LLC Sells 624 Shares of Novo Nordisk A/S (NYSE:NVO)

LVW Advisors LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,418 shares of the company’s stock after selling 624 shares during the period. LVW Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,108,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares in the last quarter. Folketrygdfondet boosted its holdings in Novo Nordisk A/S by 1.4% in the first quarter. Folketrygdfondet now owns 8,756,034 shares of the company’s stock worth $1,124,275,000 after purchasing an additional 124,770 shares during the last quarter. Capital International Investors boosted its holdings in Novo Nordisk A/S by 22.3% in the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after purchasing an additional 1,297,536 shares during the last quarter. Royal Bank of Canada boosted its holdings in Novo Nordisk A/S by 109.2% in the third quarter. Royal Bank of Canada now owns 3,643,061 shares of the company’s stock worth $331,300,000 after purchasing an additional 1,901,429 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its holdings in Novo Nordisk A/S by 1.8% in the fourth quarter. Natixis Advisors L.P. now owns 3,052,406 shares of the company’s stock worth $315,770,000 after purchasing an additional 55,333 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.2 %

Shares of Novo Nordisk A/S stock opened at $142.74 on Monday. The company’s fifty day simple moving average is $135.00 and its 200-day simple moving average is $123.71. The stock has a market capitalization of $640.55 billion, a PE ratio of 49.22, a P/E/G ratio of 1.42 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The company had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NVO shares. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Argus raised their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.